Imugene Ltd - Imugene progresses towards human studies for its PD1-Vaxx treatment by the end of 2020 Imugene progresses towards human studies for PD1-Vaxx treatment by the end of 2020

The company is well-funded to deliver on commercial and clinical milestones including the...

1 week, 2 days ago
Deep dive

Creso Pharma makes strong progress with global growth and cannabis...

The company is experiencing a strong growth trajectory driven by a strong sales pipeline and...

2 weeks, 2 days ago
Deep dive

Emyria uniquely positioned to take the lead in future of medicine as it...

The healthcare technology and services company is taking a leadership role in...

2 weeks, 3 days ago
Deep dive

MMJ Group progresses investment strategy during FY20 by extending cannabis...

The company is confident to continue its investment strategy for the remainder of 2020 and into...

3 weeks, 4 days ago

Emyria's Michael Winlo details new global partnership with UK-based Sapphire...

Emyria Ltd’s (ASX:EMD) Dr Michael Winlo caught up with Proactive's Andrew Scott after reporting that its clinical operations subsidiary, Emerald Clinics, has entered into a global partnership with UK-based Sapphire Medical Clinics. The partnership will provide a new source of data to bolster...

1 week, 2 days ago

Join Proactive

Get ahead of the curve

First with the equities news

Get our market previews and stories before the main networks.

Widest with the analysis

Not just the FTSE. Read about
opportunities from the whole
equities market.

Closest to the source

Hear directors at first-hand
or meet them in person at our events.

In at the start

Watch IPOs and access on the same terms as the institutions.